NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.

ABSTRACT:

Background

Triple Negative breast cancer (TNBC) is a poor outcome subgroup of breast cancer defined based on the absence of expression of ERα and PR and HER2 amplification. These hard to treat cancers lack targeted treatment options and are therefore treated with a standard of care (SoC) generic cocktail of DNA damaging chemotherapy, with a wide range of clinical responses. While a subset of TNBC patients respond very well to this treatment, others receive no clinical benefit and die from their disease within a short time period. We currently lack biomarkers to prospectively identify patients likely to relapse and we lack alternate treatment options.

Methods

NUP98 protein expression was investigated in patient samples using two independent tissue microarrays (TMAs), as well

SUBMITTER: Mullan PB 

PROVIDER: S-EPMC6444590 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature